Associations between smoking, components of metabolic syndrome and lipoprotein particle size

BMC Medicine

Bruce HR Wolffenbuttel²  Melanie M van der Klauw²  André P van Beek²  Edith J Feskens³  Anneke C Muller Kobold¹  Robin PF Dullaart²  H Marike Boezen⁴  Judith M Vonk⁴  Jana V van Vliet-Ostaptchouk²  Sandra N Slagter² 

[1] Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, HPC AA31, PO Box 30001, Groningen 9700 RB, The Netherlands;Department of Endocrinology, University of Groningen, University Medical Center Groningen, HPC AA31, PO Box 30001, Groningen 9700 RB, The Netherlands;Division of Human Nutrition, Wageningen University, PO Box 8129, Wageningen 6700 EV, The Netherlands;Department of Epidemiology, University of Groningen, University Medical Center Groningen, HPC AA31, PO Box 30001, Groningen 9700 RB, The Netherlands

关键词: BMI classes;    Cross-sectional;    Obesity;    Triglycerides;    Apolipoproteins;    Cholesterol;    HDL;    Smoking;    Metabolic syndrome;   

Others  :  855727
DOI  :  10.1186/1741-7015-11-195

 received in 2013-05-04, accepted in 2013-07-24,  发布年份 2013

【 摘 要 】

Background

The clustering of metabolic and cardiovascular risk factors is known as metabolic syndrome (MetS). The risk of having MetS is strongly associated with increased adiposity and can be further modified by smoking behavior. Apolipoproteins (apo) associated with low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) may be altered in MetS. This study aimed to examine the association between smoking and the following parameters: MetS and its components, levels of apolipoproteins and estimated lipoprotein particle size, separately for men and women, and in different body mass index (BMI) classes.

Methods

We included 24,389 men and 35,078 women aged between 18 and 80 years who participated in the LifeLines Cohort Study between December 2006 and January 2012; 5,685 men and 6,989 women were current smokers. Participants were categorized into three different body mass index (BMI) classes (BMI <25; BMI 25 to 30; BMI ≥30 kg/m²). MetS was defined according to the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP:ATPIII) criteria. Blood pressure, anthropometric and lipid measurements were rigorously standardized, and the large sample size enabled a powerful estimate of quantitative changes. The association between smoking and the individual MetS components, and apoA1 and apoB, was tested with linear regression. Logistic regression was used to examine the effect of smoking and daily tobacco smoked on risk of having MetS. All models were age adjusted and stratified by sex and BMI class.

Results

Prevalence of MetS increased with higher BMI levels. A total of 64% of obese men and 42% of obese women had MetS. Current smoking was associated with a higher risk of MetS in both sexes and all BMI classes (odds ratio 1.7 to 2.4 for men, 1.8 to 2.3 for women, all P values <0.001). Current smokers had lower levels of HDL cholesterol and apoA1, higher levels of triglycerides and apoB, and higher waist circumference than non-smokers (all P <0.001). Smoking had no consistent association with blood pressure or fasting blood glucose. In all BMI classes, we found a dose-dependent association of daily tobacco consumption with MetS prevalence as well as with lower levels of HDL cholesterol, higher triglyceride levels and lower ratios of HDL cholesterol/apoA1 and, only in those with BMI <30, LDL cholesterol/apoB (all P <0.001).

Conclusions

Smoking is associated with an increased prevalence of MetS, independent of sex and BMI class. This increased risk is mainly related to lower HDL cholesterol, and higher triglycerides and waist circumference. In addition, smoking was associated with unfavorable changes in apoA1 and apoB, and in lipoprotein particle size.

Please see related commentary: http://www.biomedcentral.com/1741-7015/11/196 webcite.

【 授权许可】

   
2013 Slagter et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [2]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [3]Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R: Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011, 35:971-981.
• [4]Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F: Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007, 82:509-524.
• [5]Malik VS, Willett WC, Hu FB: Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013, 9:13-27.
• [6]Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET: Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004, 89:2569-2575.
• [7]Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008, 168:1617-1624.
• [8]Lee K: Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. Asia Pac J Clin Nutr 2009, 18:280-284.
• [9]Kemper HC, Post GB, Twisk JW, Van Mechelen W: Lifestyle and obesity in adolescence and young adulthood: results from the Amsterdam Growth And Health Longitudinal Study (AGAHLS). Int J Obes Relat Metab Disord 1999, 23:S34-S40.
• [10]Nakanishi N, Takatorige T, Suzuki K: Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. Ind Health 2005, 43:295-301.
• [11]Sun K, Liu J, Ning G: Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS One 2012, 7:e47791.
• [12]Chiolero A, Faeh D, Paccaud F, Cornuz J: Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008, 87:801-809.
• [13]Chen CC, Li TC, Chang PC, Liu CS, Lin WY, Wu MT, Li CI, Lai MM, Lin CC: Association among cigarette smoking, metabolic syndrome, and its individual components: the metabolic syndrome study in Taiwan. Metabolism 2008, 57:544-548.
• [14]Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P: Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010, 64:1043-1051.
• [15]Garin MC, Kalix B, Morabia A, James RW: Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005, 90:2264-2269.
• [16]Siri PW, Krauss RM: Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. Curr Atheroscler Rep 2005, 7:455-459.
• [17]Carmena R, Duriez P, Fruchart JC: Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109:III2-III7.
• [18]Donahue RP, Orchard TJ, Stein EA, Kuller LH: Apolipoproteins AI, AII and B in young adults: associations with CHD risk factors. The Beaver County experience. J Chronic Dis 1986, 39:823-830.
• [19]Periti M, Salvaggio A, Quaglia G, Di ML, Miano L: Effect of cigarette smoking and coffee consumption on apolipoprotein B levels. Eur J Epidemiol 1990, 6:76-79.
• [20]Haarbo J, Hassager C, Schlemmer A, Christiansen C: Influence of smoking, body fat distribution, and alcohol consumption on serum lipids, lipoproteins, and apolipoproteins in early postmenopausal women. Atherosclerosis 1990, 84:239-244.
• [21]Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV: Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994, 40:586-592.
• [22]Cobbaert C, Weykamp C, Baadenhuijsen H, Kuypers A, Lindemans J, Jansen R: Selection, preparation, and characterization of commutable frozen human serum pools as potential secondary reference materials for lipid and apolipoprotein measurements: study within the framework of the Dutch project "Calibration 2000". Clin Chem 2002, 48:1526-1538.
• [23]Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP, Ormel J, Wolffenbuttel BH: Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008, 23:67-74.
• [24]Geslain-Biquez C, Vol S, Tichet J, Caradec A, D'Hour A, Balkau B: The metabolic syndrome in smokers. The D.E.S.I.R. study. Diabetes Metab 2003, 29:226-234.
• [25]Zhu S, St-Onge MP, Heshka S, Heymsfield SB: Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 2004, 53:1503-1511.
• [26]Weitzman M, Cook S, Auinger P, Florin TA, Daniels S, Nguyen M, Winickoff JP: Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 2005, 112:862-869.
• [27]Wilsgaard T, Jacobsen BK: Lifestyle factors and incident metabolic syndrome. The Tromso Study 1979–2001. Diabetes Res Clin Pract 2007, 78:217-224.
• [28]Nakashita Y, Nakamura M, Kitamura A, Kiyama M, Ishikawa Y, Mikami H: Relationships of cigarette smoking and alcohol consumption to metabolic syndrome in Japanese men. J Epidemiol 2010, 20:391-397.
• [29]Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006, 38:52-63.
• [30]Berlin I, Lin S, Lima JA, Bertoni AG: Smoking status and metabolic syndrome in the multi-ethnic study of atherosclerosis. A cross-sectional study. Tob Induc Dis 2012, 10:9. BioMed Central Full Text
• [31]Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM: Insulin resistance and cigarette smoking. Lancet 1992, 339:1128-1130.
• [32]Oh SW, Yoon YS, Lee ES, Kim WK, Park C, Lee S, Jeong EK, Yoo T, Korea National Health and Nutrition Examination Survey: Association between cigarette smoking and metabolic syndrome: the Korea national health and nutrition examination survey. Diabetes Care 2005, 28:2064-2066.
• [33]Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M: Association between cigarette smoking, white blood cell count, and metabolic syndrome as defined by the Japanese criteria. Intern Med 2007, 46:1167-1170.
• [34]Chelland CS, Moffatt RJ, Stamford BA: Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008, 201:225-235.
• [35]Saarni SE, Pietilainen K, Kantonen S, Rissanen A, Kaprio J: Association of smoking in adolescence with abdominal obesity in adulthood: a follow-up study of 5 birth cohorts of Finnish twins. Am J Public Health 2009, 99:348-354.
• [36]Chiodera P, Volpi R, Capretti L, Speroni G, Necchi-Ghiri S, Caffarri G, Colla R, Coiro V: Abnormal effect of cigarette smoking on pituitary hormone secretions in insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) 1997, 46:351-357.
• [37]Cryer PE, Haymond MW, Santiago JV, Shah SD: Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976, 295:573-577.
• [38]Friedman AJ, Ravnikar VA, Barbieri RL: Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril 1987, 47:398-401.
• [39]Pasquali R, Vicennati V: Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J Obes Relat Metab Disord 2000, 24:S47-S49.
• [40]Houston TK, Person SD, Pletcher MJ, Liu K, Iribarren C, Kiefe CI: Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study. BMJ 2006, 332:1064-1069.
• [41]Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790-797.
• [42]Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE: Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2005, 28:2501-2507.
• [43]Hughes K, Choo M, Kuperan P, Ong CN, Aw TC: Cardiovascular risk factors in relation to cigarette smoking: a population-based survey among Asians in Singapore. Atherosclerosis 1998, 137:253-258.
• [44]Green MS, Jucha E, Luz Y: Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J 1986, 111:932-940.
• [45]Barutcu I, Esen AM, Degirmenci B, Acar M, Kaya D, Turkmen M, Melek M, Onrat E, Esen OB, Kirma C: Acute cigarette smoking-induced hemodynamic alterations in the common carotid arter–a transcranial Doppler study–. Circ J 2004, 68:1127-1131.
• [46]Leone A: Smoking and hypertension: independent or additive effects to determining vascular damage? Curr Vasc Pharmacol 2011, 9:585-593.
• [47]Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR: Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001, 37:187-193.
• [48]Niskanen L, Laaksonen DE, Nyyssönen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, Salonen JT: Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004, 44:859-865.
• [49]Mundal R, Kjeldsen SE, Sandvik L, Erikssen G, Thaulow E, Erikssen J: Predictors of 7-year changes in exercise blood pressure: effects of smoking, physical fitness and pulmonary function. J Hypertens 1997, 15:245-249.
• [50]Chu NF, Ding YA, Wang DJ, Shieh SM: Relationship between smoking status and cardiovascular disease risk factors in young adult males in Taiwan. J Cardiovasc Risk 1996, 3:205-208.
• [51]Cuesta C, Sánchez-Muniz FJ, García-La Cuesta A, Garrido R, Castro A, San-Felix B, Domingo A: Effects of age and cigarette smoking on serum concentrations of lipids and apolipoproteins in a male military population. Atherosclerosis 1989, 80:33-39.
• [52]Shearman AM, Demissie S, Cupples LA, Peter I, Schmid CH, Ordovas JM, Mendelsohn ME, Housman DE: Tobacco smoking, estrogen receptor alpha gene variation and small low density lipoprotein level. Hum Mol Genet 2005, 14:2405-2413.
• [53]Walldius G, Jungner I: Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004, 255:188-205.
• [54]Arsenault BJ, Lemieux I, Després JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM: HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009, 206:276-281.
• [55]Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, Collins R, International Studies of Infarct Survival Collaborators: The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009, 30:2137-2146.
• [56]Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
• [57]Sacks FM, Campos H: Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003, 88:4525-4532.
• [58]El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, Boekholdt SM: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49:547-553.
• [59]Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol 2006, 97:943-946.
• [60]Kwon CH, Kim BJ, Kim BS, Kang JH: Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. Metabolism 2011, 60:1136-1141.
• [61]Noonan D, Jiang Y, Duffy SA: Utility of biochemical verification of tobacco cessation in the Department of Veterans Affairs. Addict Behav 2013, 38:1792-1795.